Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study

D. D. Von Hoff, R. Kronmal, R. V. O'Toole, E. A. Surwit, J. J. Hutton, D. S. Alberts

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Fourteen evaluable patients with advanced ovarian cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was granulocytopenia with 50% of patients having granulocyte counts of <1,000/μl. Based on this study and one other previously published trial, fludarabine phosphate does not appear to be an active agent for patients with refractory ovarian cancer.

Original languageEnglish (US)
Pages (from-to)146-148
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number2
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study'. Together they form a unique fingerprint.

  • Cite this